相关实验视频

Updated: Jul 24, 2025

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

用葡萄糖调制的化疗药物的淋巴内注射改善了它们的抗癌作用

Ariunbuyan Sukhbaatar¹, Shiro Mori¹, Kiyoto Shiga²

¹Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi 980-8575, Japan; Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi 980-8575, Japan; Division of Oral and Maxillofacial Oncology and Surgical Sciences, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi 980-8575, Japan.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|July 8, 2023

概括

这项研究表明,使用高透压溶液的淋巴药物递送系统 (LDDS) 可以改善淋巴结中的化疗药物保留,提高癌症治疗效率并减少副作用.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
药物输送系统药物输送系统

背景情况:

淋巴结转移 (LNM) 显著影响癌症预后,需要改进治疗策略.
目前的化疗输送方法往往导致全身副作用和转移部位的药物度低于最佳水平.

研究的目的:

研究使用低粘度的高透压药物溶液治疗淋巴结转移的淋巴药物递送系统 (LDDS) 的疗效.
为了确定LDDS是否与静脉注射相比,增强了淋巴结中的药物保留和积累.

主要方法:

通过LDDS在高奥斯莫斯压力但低粘度下给予epirubicin或nimustine.
生物光分析以量化淋巴结中的药物积累和保留.
组织病理学检查以评估组织损伤.
药理动力学分析,以评估治疗反应.

主要成果:

与静脉注射相比,LDDS显著增强了淋巴结中的药物积累和保留.
组织病理学发现LDDS治疗组的组织损伤最小.
药物动力学数据表明,由于淋巴结中药物度增加,治疗反应有所改善.

结论:

通过LDDS给药的高透压药物溶液显示出改善淋巴结转移治疗疗效的希望.
这种方法可以减少化疗副作用,降低所需剂量,并增加淋巴结中的药物保留.
需要进一步的临床试验来验证LDDS的广泛临床应用.

关键词:

化疗化疗是一种化学疗法.埃皮鲁比是一种类药物.淋巴结转移是淋巴结的转移.淋巴系统的药物输送.尼莫斯提因 (Nimustine) 是一种药物.这种压力是奥斯莫斯压力.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...